Patients with systemic lupus erythematosus (SLE) have a high incidence of invasive fungal infection (IFI) and poor prognosis. The main infection sites are blood, respiratory system, skin soft tissue and central ner-vous system; most pathogens were Cryptococcus neoformans, Candida albicans, Aspergillus fumigatus and so on. Risk factors of IFI in SLE patients are very complex, the application of glucocorticoid and high score of SLE activity are definite risk factors. There is little progress in the detection of biomarkers of fungal infection in SLE patients, including detection of Candida albicans germ tube antibody and cryptococcal antigen, polymerase chain reaction, as well as detection of pathogen metagenome. Sensitivity and specificity of the relevant biomarkers, as well as the feasibility of the clinical application need further exploration and clinical practice. The accurate judgment can be made only through analysis on risk factors, biomarkers, clinical symptoms, signs and drug use of SLE patients.